< Zurück < Zurück
von 33
Weiter > Weiter >
Top-News
< Zurück < Zurück
von 33
Weiter > Weiter >
  • Startseite
  • Aktien
  • Palatin Technologies Aktie
  • News
  • Jetzt traden

    • Palatin Technologies News

    2,44 $ +3,83% +0,09 $
    In : 2,2749 € | 26.05.23 22:10:00 AMEX aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3DTUW
    ISIN: US6960775020
    US-Symbol: PTN
    Typ: Aktie

    Palatin Technologies News

    < Zurück < Zurück
    von 33
    Weiter > Weiter >
    16.05.23 - PR Newswire
    Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
    Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update PR Newswire
    11.05.23 - PR Newswire
    Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023
    Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023 PR Newswire
    09.05.23 - PR Newswire
    Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference
    Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference PR Newswire
    08.05.23 - PR Newswire
    Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar
    Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar PR Newswire
    01.05.23 - PR Newswire
    Palatin Technologies to Host Key Opinion Leader Webinar
    Palatin Technologies to Host Key Opinion Leader Webinar PR Newswire
    27.04.23 - PR Newswire
    Palatin Presents Initial Dry Eye Disease Phase 3 Clinical Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference
    Palatin Presents Initial Dry Eye Disease Phase 3 Clinical Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference PR Newswire
    25.04.23 - PR Newswire
    Palatin Presents Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Regarding a Potential Treatment for Glaucoma
    Palatin Presents Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Regarding a Potential Treatment for Glaucoma PR Newswire
    19.04.23 - PR Newswire
    Palatin Announces Preliminary Third Quarter Fiscal 2023 Vyleesi® Product Revenue Results
    Palatin Announces Preliminary Third Quarter Fiscal 2023 Vyleesi® Product Revenue Results PR Newswire
    18.04.23 - PR Newswire
    Pre-Clinical Data of Palatin's Melanocortin Agonist Demonstrating Therapeutic Effects in Diabetic Retinopathy and Uveitis Published in the International Journal of Molecular Sciences
    Pre-​Clinical Data of Palatin's Melanocortin Agonist Demonstrating Therapeutic Effects in Diabetic Retinopathy and Uveitis Published in the International Journal of Molecular ...
    02.03.23 - PR Newswire
    Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's Oral Formulation of PL8177 Demonstrating Therapeutic Effects in Inflammatory Bowel Disease
    Frontiers in Immunology Publishes Pre-​Clinical Study of Palatin's Oral Formulation of PL8177 Demonstrating Therapeutic Effects in Inflammatory Bowel Disease PR Newswire
    28.02.23 - PR Newswire
    Palatin Issued Patent on Vyleesi® (Bremelanotide Injection) For Hypoactive Sexual Desire Disorder in Patients With Controlled Hypertension
    Palatin Issued Patent on Vyleesi® (Bremelanotide Injection) For Hypoactive Sexual Desire Disorder in Patients With Controlled Hypertension PR Newswire
    15.02.23 - PR Newswire
    Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
    Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update PR Newswire
    10.02.23 - PR Newswire
    Palatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023
    Palatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023 PR Newswire
    19.01.23 - PR Newswire
    Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease
    Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease PR Newswire
    18.01.23 - PR Newswire
    Palatin Receives $4.7 Million of Non-Dilutive Funding
    Palatin Receives $4.7 Million of Non-​Dilutive Funding PR Newswire
    10.01.23 - PR Newswire
    Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions
    Frontiers in Immunology Publishes Pre-​Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions PR Newswire
    05.01.23 - PR Newswire
    Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results
    Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results PR Newswire
    14.11.22 - PR Newswire
    Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
    Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update PR Newswire
    09.11.22 - PR Newswire
    Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022
    Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022 PR Newswire
    31.10.22 - PR Newswire
    Palatin Announces $10 Million Registered Direct Offering
    Palatin Announces $10 Million Registered Direct Offering PR Newswire
    < Zurück < Zurück
    von 33
    Weiter > Weiter >

    Newssuche

    Videos

    26.05.23 +2,52%
    Technical Trading: Gold kurzfristig Long
    Gold Long Typ: Turbo Open End WKN: HC1RDM Hebel: 7 Laufzeit: OpenEnd Einstieg: Market ... Mehr »